TransCode Therapeutics, Inc. Profile Avatar - Palmy Investing

TransCode Therapeutics, Inc.

TransCode Therapeutics, Inc., a biopharmaceutical company, engages in the development and commercialization of drugs and diagnostics for treating and identifying metastatic disease. Its lead therapeutic candidate, TTX-MC138, is a preclinical stage produc…

Biotechnology
US, Boston [HQ]
US · Macroeconomic Factors/Risks · Forecasts

Macro

TransCode Therapeutics, Inc. mainly operates in US (Alpha-2: US, Alpha-3: USA)

United States
Analysis Results
B Overall Rating
19 Analyzed Indicators
B Annual Indicators Rating
16 Analyzed Indicators
B+ Monthly Indicators Rating
3 Analyzed Indicators
Breakdown

All indicators comes from high quality sources, such as the world bank, OECD, FRED and manuel datasets such as Premiums by Prof. Damodaran.

End of RNAZ's Analysis
CIK: 1829635 CUSIP: 89357L105 ISIN: US89357L3033 LEI: - UEI: -
Secondary Listings
RNAZ has no secondary listings inside our databases.